The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval: − 0.30 to 0.80) (P = 0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R 2 to 0.50 with a slope of 1.44 (P = 0.0021). Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.
Introduction
Over the last few years, new therapeutic options and choices have been identified thanks to the discovery of new therapies for metastatic castration-resistant prostate cancer (mCRPC) [1, 2] . Today, the real problem is to identify the best sequence of drugs because differences among study populations and lack of biomarkers make it difficult to compare the obtained results from clinical trials [3, 4] . Until 2010, the standard therapy for mCRPC was docetaxel. Subsequently, in other research on mCRPC, clinical factors that benefit from androgen axis target and other therapies have been analyzed to support physicians in their treatment decisions for individual patients [5] [6] [7] . Introduction of second-generation hormonal agents, such as abiraterone and enzalutamide, has improved the treatment outcomes in CPRC [8] . AA is converted in vivo to abiraterone, whose mechanism of action is based on the inhibition of enzymes responsible for the production of androgens. It blocks the activity of enzyme 17α-hydroxylase/C17,20-lyase (CYP17) and extragonadal and testicular androgen biosynthesis, stopping tumor growth in mCRPC [9] [10] [11] [12] [13] [14] . The clinical benefits and safety of AA were evaluated in two phase 3, multinational, randomized, double-blind, placebo-controlled studies, respectively conducted at 147 sites in 13 countries and at 151 sites in 12 countries: COU-AA-301 [15] and COU-AA-302 [16] . The use of these drugs has been proven effective when compared with placebo both in chemonaive patients and in those progressing after first-line chemotherapy with docetaxel. The authors demonstrated in these two studies that patients treated with abiraterone had a statistically significant improvement in OS, prostate-specific antigen (PSA) progression, progression-free survival (PFS), PSA response rate, and PFS. Further, abiraterone treatment had delayed pain progression and deterioration in functional status when compared with prednisone alone in patients with mCRPC. Considering the validity of these clinical trials, The US Food and Drug Administration and the European Medicines Agency approved the administration of abiraterone as a standard recommended therapy for the treatment of mCRPC progressing after docetaxel plus prednisone [17] . The main purpose of this retrospective study was to evaluate the safety and efficacy of abiraterone (ZYTIGA, Janssen-Cilag International NV Turnhoutseweg, Beerse) in patients with mCRPC progressing after docetaxel plus prednisone in our clinical reality. In particular, analysis of the reduction in serum PSA was assessed as the primary endpoint for evaluating the effectiveness of treatment with abiraterone. Secondary endpoints were pain relief, tolerability, overall survival (OS), and PFS.
Study design
This retrospective study was conducted to evaluate the safety and efficacy of 1000 mg abiraterone (four capsules of 250 mg) as a single daily oral dose along with 5 mg prednisone twice daily in patients diagnosed with mCRPC. In particular, the objectives were as follows: (i) evaluate the effectiveness of the treatment in terms of reduction in serum PSA levels; (ii) assess any significant relationship between PSA response and OS; (iii) evaluate whether PSA response to treatment may serve as a predictor of OS; we attempted to identify a link between PSA response rate and significantly higher OS; and (iv) analyze the intensity of the link between variability of PSA response and pain relief. The link of dependence between the two variables, PSA and OS, was analyzed using a linear regression model. The OS and the PSA represented the dependent variable Y and the independent variable X, respectively. The values of the coefficient of determination R 2 (which represents the proportion of variation between the observed values of Y explained by the linear regression of Y on X) and the slope values (increase in Y for any increase in X units) were considered. Data were represented by scatter plot and regression line.
Patients and methods
We retrospectively analyzed 60 patients diagnosed with mCRPC between December 2013 and March 2017 at the Medical Oncology Unit of the University Palermo and ARNAS Hospital Civico of Palermo. Similar to previous studies [18, 19] , we considered only patients who met the following inclusion criteria: (i) had a histologically or cytologically confirmed diagnosis of mCRPC in progression after prednisone plus docetaxel failure according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1); (ii) had a performance status of 0-2 according to the Eastern Cooperative Oncology Group; and (iii) had clinical or radiological evidence of metastatic disease (number of lesions ≥ 1) and adequate liver, renal, and blood functionality.
We excluded patients who were hypersensitive to AA and its excipients or other formulation components, had a diagnosis of other malignancies (with the exception of properly treated basal cell carcinoma of the skin), or had serious comorbidities not adequately controlled by other ongoing therapies (e.g. liver disease, diabetes, infections, heart disease, etc.). All clinical and pathological data were retrieved from the database. In our clinical practice, abiraterone treatment was carried out as a part of clinical care in our clinical practice.
Study assessments Evaluation of response
We assessed the response rate in terms of reduction of both PSA and measurable disease (4 weeks after the end of treatment) before the start of each treatment cycle, and evaluated it every 3 months until disease progression. Whenever there was an increase in PSA, patients underwent radiological examinations (such as chest and abdomen computed tomography scans) every 6 months and always before administration of therapy. Bone scan was performed before starting the treatment, and then every 6 or 12 months as per the physician's discretion and patients' characteristics. If patients did not show measurable disease, we considered as response to treatment a sustained reduction in serum PSA levels of 50% or more from baseline.
Modality of administration
Patients received abiraterone as 250 mg tablets to be taken as a single dose of 1000 mg daily (four tablets of 250 mg) with prednisone at 5 mg twice daily for 4 weeks until disease progression or death or until the development of severe complications or unacceptable adverse events.
Statistical analysis
Normality of distribution was checked using univariate indices of Kurtosis and Skewness with an acceptance threshold of 1. No variable violated normality indices.
Descriptive statistical analyses were carried out to provide a sociodemographic representation of the study group patients and to explore how to distribute the examined variables. Afterwards, inferential statistical analyses were performed to detect any significative relationships among the considered variables. PFS and OS were calculated from the date of the start of treatment until the date of disease progression or death from any cause for PFS and until the date of last follow-up, death, or final follow-up for OS. The cutoff date was March 2017. PFS and OS curves were estimated using the Kaplan-Meier method. In contrast, in order to analyze the correlation between PSA response and OS, or the time of diagnosis and/or treatment until death, the linear correlation index Bravais-Pearson (r), with a 95% confidence interval (CI), was used. This index was used to measure the intensity of the correlation between the variability in PSA response and the reduction in pain. In addition, to assess the role of PSA in predicting OS in our sample, we conducted linear regression analysis.
Given the sample size, parametric statistics were used, and a P value of 0.05 was considered as the threshold to determine the significance of the obtained results. Data processing was performed using IBM SPSS statistics for Windows (version 22.0; IBM Corp., Armonk, New York, USA).
Results

Treatment response and follow-up
The demographic, clinical, and pathological features of 60 patients with mCRPC are reported in Table 1 . At diagnosis, patients were aged between 45 and 86 years, with an average age of 65 years. Nearly all patients were able to perform a median of 12.0 (range: 0.2-17.2) cycles.
The response rate of total PSA after four cycles was 70% (84 of 120 patients). Treatment with abiraterone was well tolerated and there was a good level of disease control (complete response + partial response + stable disease: 50%). After a median duration of follow-up of 12.4 months, no patient had a complete response to treatment, 27 (45%) patients had a partial response to treatment, and 20 (33%) patients had stable disease, whereas 13 (22%) experienced disease progression.
PSA level reduction of more than 50%
In patients treated with abiraterone, the average reduction was 43% (95% CI: 49.80-45.02). We found a PSA serum level decrease of more than 50% to be related to better survival.
We considered PSA progression as follows: (a) an increase in PSA by at least 25% from baseline in patients who had failed to achieve a significant reduction (≥50%) in serum PSA levels during treatment; and (b) a greater than or equal to 50% increase in the lowest level in patients achieving a significant reduction (≥50%) of serum PSA levels under treatment.
Overall survival analysis
Among the 60 patients enrolled in this study, updated interim analysis of survival (until last follow-up in March 2017) showed a median OS of 14 months (95% CI: 12.926-15.074) (Fig. 1) .
The Bravais-Pearson index showed a positive correlation between the response rate of PSA and OS, with a value of 0.60 (95% CI: 0.28-0.85) (P = 0.002) ( Table 2) .
Furthermore, regression analysis between PSA response rate and OS showed a value of R 2 of 0.50 with a slope of 1.44 (P = 0.0021) (Fig. 2) .
Progression-free survival analysis time
In this study, the median duration of response was 4 (range: 2.8-4 months), whereas the median time to progression was 5 months (95% CI: 4.425-5.575) (Fig. 3) .
Tolerability
In the group of patients treated with abiraterone, treatment-related toxicity was not relevant and side effects were evaluated after each course of therapy and reported in line with the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, version 4.0. The most common adverse events were hypertension, hypokalemia, and fluid retention, which presented only in 15% of patients.
Pain response
Pain reduction assessed by the Visual Analogue Scale (VAS) showed a response to pain in 48% of patients. PSA, prostatic-specific antigen. **P < 0.01.
Fig. 1
Kaplan-Meier plot of median overall survival (mOS) (interim analysis) (N = 60). CI, confidence interval; PSA, prostate-specific antigen.
Abiraterone: a retrospective study Cicero et al. 1049 In addition, improvement in the quality of life was identified with a reduction in pain symptoms in 61% of patients with a VAS score of less than 22 points and a reduced use of analgesics in 56% of patients. The correlation index Bravais-Pearson (r) was also used to analyze the intensity of association between the variable of PSA response and reduction in pain. The results reveal that there is a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% CI: − 0.30 to 0.80) (P = 0.005) ( Table 3 ). The higher the PSA response to treatment, the better the response in terms of pain relief.
Discussion
Each trial provided confirmation that mCRPC remains in part an androgen-driven disease even after progression on chemotherapy and that androgen blockade can lead to improved patient outcomes [20, 21] . This retrospective analysis was designed to demonstrate the efficacy and safety of abiraterone in patients with mCRPC, considering the reduction in serum levels of PSA, reduced pain, safety, PFS, response rate, and OS as responses to treatment. Select demographic and medical characteristics were also investigated. The PSA response was considered to be possible predictive and/or moderating factors of OS. In our patients, treatment with abiraterone was well tolerated, and a modest objective response rate and a good reduction in PSA levels were obtained. This study complies with the studies reported in the literature [22, 23] , in which the analysis of serum PSA levels represented the surrogate endpoint assessing the effectiveness of the treatment. In addition, we decided to analyze the possible correlation between PSA response and pain reduction, seeing that pain was more present whenever a better response of PSA to treatment occurred. Therefore, we wanted to understand, given the strong association between the two variables, whether the PSA response could be a predictive factor for increasing the OS rate by using linear regression analysis. The positive correlation between PSA response and OS (β =0.40, P < 0.01), obtained by linear regression analysis, revealed that PSA response is an important predictor of OS. The slope values suggest that, for every month of PFS, OS increases by about 1.5 months after the chemotherapy (Fig. 3) . This correlation set apart our research from similar findings obtained by Facchini et al. [23] in their study, where they demonstrated that an early PSA decline was associated with longer OS and PFS. Furthermore, the efficacy of PSA as an important clinical predictor has been documented by Verzoni et al. [22] in their retrospective cohort study. Their findings, obtained by multivariate analysis, showed that only PSA and Gleason score were independent predictors of long-term treatment response to abiraterone, and no other clinical factors (alkaline phosphatases levels, lactate dehydrogenase, age, M-staging at diagnosis or site of metastases) were significantly clinical predictors of sustained response to this drug. Therefore, we could affirm that our results, in keeping with these two Italian studies, validate PSA as an early potential predictive marker of AA response, but other prospective studies are needed to Regression analysis between PSA response and overall survival of patients with mCRPC (N = 60). mCRPC, metastatic castrationresistant prostate cancer; OS, overall survival; PSA, prostate-specific antigen. Kaplan-Meier plot of median progression-free survival (mPFS) (interim analysis) (N = 60).CI, confidence interval. confirm it. In this retrospective study there are limitations that undoubtedly are highlighted in comparison with large studies [15] . These include (besides the narrow dimension of the sample) the criteria for response evaluation and the difference in the definition of mCRPC in our clinical practice (three consecutive increases in PSA serum, 2 weeks apart, resulting in two increments above the lowest point of 50%) when compared with the last criteria of the PSA working group (a sequential increase in PSA for a minimum of 1 week, to weekly intervals with a PSA level greater than 2 ng/ml as a starting value). Our results are in agreement with those of COU-AA. Furthermore, as in COU-AA-301 [15] , the most common adverse events in our study were hypokalemia, fluid retention, and hypertension. The efficacy of Abiraterone was also shown across all specified secondary endpoints. Moreover, abiraterone demonstrated its efficacy as a valid therapeutic option in patients with prostate cancer. Furthermore, we observed a better response in terms of pain relief in patients when the PSA response to treatment was higher. In fact, the VAS showed a response to pain in 48% of our patients and an improvement in the quality of life due to a reduction in pain symptoms; we also noticed a reduction in metastatic bone. This is in accordance with studies in the literature that have shown a high efficacy of abiraterone in improving multiple skeletal disease [24] . This association should be further investigated in future studies. The results show that continued androgen-receptor signaling contributes to disease progression. Thus, abiraterone use could be considered a valid treatment option for mCRPC. The results obtained from this retrospective study, similar to the outcomes of clinical trials reported in the literature [25] [26] [27] [28] , demonstrate that the inhibition of androgen biosynthesis by AA prolonged the OS among patients with metastatic castration-resistant prostate cancer who had previously received chemotherapy. Therefore, abiraterone administered daily at a dose of 1000 mg orally is an excellent treatment strategy for most patients with mCRPC progressing after treatment with docetaxel plus prednisone. It is important to have all treatment options available, including androgen receptor-targeted and nonandrogen receptor-targeted therapies [29] [30] [31] . There is a need to more closely tailor therapies to individual patient profiles by clinical prognostic models and novel biomarkers of response or resistance [32, 33] . To date, many clinical trials [34] [35] [36] [37] have attempted to define biomarkers that may be used to define the best sequence in order to to achieve better results in terms of OS because, as explained by Della Pepa et al. [4] , a standard treatment sequence does exist. In fact the oncologist chooses the most appropriate treatment strategy according to the clinical profile of the patient (comorbidities, general condition, age, tolerability profile) and their own experience with the drug.
Finally, future research must include active comparisons with available options to provide robust evidence of increased benefit and identify the most efficacious sequence of treatment for the management of mCRPC.
